Hereditary Pancreatitis Amlodipine Trial
Authors:
- Mark E. LoweMLMark E. Lowe
- Beth D. ElinoffBEBeth D. Elinoff
- David C. WhitcombDWDavid C. Whitcomb
- 1 November 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Pancreas
- Vol. 35 (4) , 308-312
Abstract
Hereditary pancreatitis (HP) is a form of recurrent acute pancreatitis (AP) mediated by mutations in cationic trypsinogen (PRSS1). Mutations cluster in the calcium-associated regulator regions of PRSS1. In rats, calcium-channel blockers (CCB) prevent hyperstimulation-associated AP. Because of the potential importance of hyperstimulation in triggering episodes of AP in HP, we designed a pilot study to evaluate the safety and potential benefit of CCB use in HP. Subjects 6 years or older had a PRSS1 mutation, recurrent AP, and pain. Total study duration was 16 weeks. Amlodipine was given during weeks 0 to 11. Dose (2.5, 5, or 10 mg) was based on weight (range, 0.08-0.17 mg x kg(-1) x d(-1)). Subjects filled a daily diary including pain (0-10 scale) and blood pressure reading. Clinical assessments occurred at weeks -4, 0, 1, 2, 6, 10, 11, and 12. Subjects filled a Medical Outcomes Study Short-Form Survey version 2 (SF-10 for children <14 years old) at weeks -4, 0, 6, and 10. Data were compared for weeks -4 to 0 and 6 to 10. Nine subjects signed informed consent (4 males; 12-52 years old). Four were excluded during the screening phase. Drug was discontinued in one due to development of unilateral lower-extremity numbness. Four subjects (12-31 years old) completed the study. Mean blood pressure, laboratory tests, physical findings, and daily pain scores did not clinically significantly differ before and during drug therapy, but all reported reduced symptoms. Three reduced analgesic use. Three had improved scores on the Medical Outcomes Study Short-Form Survey version 2. Amlodipine is generally safe in subjects with HP and does not increase pain or episodes of AP. Further research into the mechanism of CCB on pancreatitis would be important to provide a pathophysiologic basis to support further trials in HP.Keywords
This publication has 31 references indexed in Scilit:
- Fatty Acid Ethyl Esters Cause Pancreatic Calcium Toxicity via Inositol Trisphosphate Receptors and Loss of ATP SynthesisGastroenterology, 2006
- Value of genetic testing in the management of pancreatitisGut, 2004
- A randomized, placebo-controlled trial of amlodipine in children with hypertensionThe Journal of Pediatrics, 2004
- Elevated calcium and activation of trypsinogen in rat pancreatic aciniGut, 1997
- Ca2+ Flow via Tunnels in Polarized Cells: Recharging of Apical Ca2+ Stores by Focal Ca2+ Entry through Basal Membrane PatchCell, 1997
- Depletion of Intracellular Calcium Stores Activates a Calcium Conducting Nonselective Cation Current in Mouse Pancreatic Acinar CellsJournal of Biological Chemistry, 1996
- Calcium Channel Blockade Inhibits Release of TNFα and Improves Survival in a Rat Model of Acute PancreatitisPancreas, 1996
- A model for receptor-regulated calcium entryCell Calcium, 1986
- The refined crystal structure of bovine β-trypsin at 1·8 Å resolutionJournal of Molecular Biology, 1975
- The binding of Ca2 to trypsinogen and its relation to the mechanism of activationBiochemical and Biophysical Research Communications, 1967